Explore

Time-Restricted Eating Shows Promise in Slowing Early-Stage Huntington's Disease Progression

Time-Restricted Eating Shows Promise in Slowing Early-Stage Huntington's Disease Progression

A 12-week pilot study led by Oregon Health & Science University (OHSU) has found that time-restricted eating, a form of intermittent fasting, may help slow the progression of early-stage Huntington's disease. Participants in the study limited their food consumption to a six-to-eight-hour window daily, successfully maintaining their weight and lean muscle mass. The research, published in Nature Metabolism, is the first clinical study to investigate time-restricted eating in individuals with Huntington's disease. Key findings include an average improvement of 0.5 points on the composite Unified Huntington's Disease Rating Scale (cUHDRS), a measure of disease severity that typically declines annually. Additionally, blood levels of neurofilament light, a biomarker indicating nerve cell damage, decreased by an average of 13%, a reversal of the expected increase as the disease progresses. Researchers also observed improvements in mitochondrial activity, which is crucial for cellular energy production and often i...

Epstein-Barr Virus Reactivation Linked to Multiple Sclerosis Relapses in New Study

Epstein-Barr Virus Reactivation Linked to Multiple Sclerosis Relapses in New Study

A recent longitudinal study has provided strong evidence suggesting that episodic reactivation of the Epstein-Barr virus (EBV) may contribute to multiple sclerosis (MS) relapses. Researchers analyzed blood samples from 114 MS patients and 21 healthy controls, including samples collected up to 90 days before confirmed relapses. Using advanced techniques such as single-cell RNA sequencing, flow cytometry, bulk RNA sequencing, and viral transcript analyses, the study identified distinct immune changes occurring weeks to months prior to clinical attacks. Specifically, B cells, which harbor dormant EBV, showed significant pre-relapse changes, including increased EBV activity and activation of antiviral and inflammatory pathways. Atypical B cells associated with viral infection and autoimmunity expanded by a median of 60% in paired patient samples before a relapse. The immune signature, appearing as early as three months before symptom onset, was enriched for genes previously linked to MS susceptibility, indicat...

NIH Researcher Paule Joseph Highlights Link Between Sense of Smell and Brain Health

NIH Researcher Paule Joseph Highlights Link Between Sense of Smell and Brain Health

Paule Joseph, a chemosensory researcher and senior investigator at the National Institutes of Health (NIH), emphasizes the significant connection between an individual's sense of smell and their overall brain health. Joseph, who co-directs the National Smell and Taste Center, suggests that the ability, or inability, to smell can offer crucial insights into neurological well-being. Her research at the Section of Sensory Science and Metabolism specifically investigates the intricate relationships among taste, smell, metabolic regulation, and brain function. During the COVID-19 pandemic, Joseph co-founded the Global Consortium for Chemosensory Research to facilitate international studies on the loss of taste and smell, a common symptom associated with the virus. This initiative underscores the growing recognition of chemosensory functions as indicators of broader health conditions. The findings from her work suggest that paying attention to one's olfactory senses could be a simple yet effective way to monitor...

Michael J. Fox Foundation Launches $2.5 Billion 'All Grit. No Quit.' Campaign to Accelerate Parkinson's Research

Michael J. Fox Foundation Launches $2.5 Billion 'All Grit. No Quit.' Campaign to Accelerate Parkinson's Research

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has announced the launch of its ambitious multi-year 'All Grit. No Quit.' fundraising campaign, aiming to raise $2.5 billion. This initiative is dedicated to accelerating the development of next-generation treatments and ultimately a cure for Parkinson's disease. The campaign, which quietly began in 2024, has already secured over $1.75 billion from more than 276,000 donors, surpassing its halfway mark. This marks MJFF's first multi-year fundraising campaign and comes at a critical juncture of scientific opportunity in Parkinson's research. The funds will advance the Foundation's Strategic Research Agenda, which has already led to significant progress, including the discovery of a new Parkinson's biomarker in 2023 and the approval of 23 new drugs over the past decade.

Oregon Health Science University Study Shows Intermittent Fasting May Slow Huntington's Disease Progression

Oregon Health Science University Study Shows Intermittent Fasting May Slow Huntington's Disease Progression

A 12-week pilot study conducted by Oregon Health & Science University (OHSU) indicates that time-restricted eating, a form of intermittent fasting, may offer a promising approach to slowing the progression of Huntington's disease. The study, published in Nature Metabolism, involved people with early-stage Huntington's disease who limited their food consumption to a six-to-eight-hour window daily. Participants successfully adhered to the eating schedule, maintained their body weight and lean muscle mass, and reported few side effects. Researchers observed improvements in measures of disease severity, a reduction in a blood biomarker linked to nerve cell damage (neurofilament light), and enhanced cellular energy production. This marks the first clinical study to investigate time-restricted eating in individuals with Huntington's disease, a rare, inherited neurological disorder that progressively damages nerve cells.

Stratified Medicine Advances with AI and Genomic Technologies for Personalized Treatment

Stratified Medicine Advances with AI and Genomic Technologies for Personalized Treatment

Stratified medicine, also known as precision medicine, is evolving rapidly through the integration of artificial intelligence (AI) and genomic technologies. This approach focuses on customizing medical treatment for individual patients by utilizing biomarkers to identify specific subgroups within a diagnosis. The advancements allow for more targeted and effective therapies. AI and genomic technologies are enhancing the analysis of complex multimodal data, which includes imaging, physiological signals, and electronic health records. This comprehensive data analysis supports earlier diagnosis, more refined phenotyping, and improved risk stratification across various medical conditions. High-throughput pluripotent stem cell models combined with AI modeling are accelerating the development of precision medicine, particularly in fields such as oncology, neurodevelopmental and neurodegenerative disorders, and metabolic diseases. This shift moves away from a one-size-fits-all medical approach towards treatments t...

Bill Ackman Commits $400 Million to New Brain Research Institute Following Family Health Crisis

Bill Ackman Commits $400 Million to New Brain Research Institute Following Family Health Crisis

Bill Ackman Commits $400 Million to New Brain Research Institute Following Family Health Crisis

Gut Bacteria at MS Diagnosis May Predict Disease Course, Study Suggests

Gut Bacteria at MS Diagnosis May Predict Disease Course, Study Suggests

A recent study indicates that the composition of gut bacteria at the time of a Multiple Sclerosis (MS) diagnosis could provide early insights into how the disease will progress. Researchers observed significant differences in the overall gut microbiome between newly diagnosed MS patients and healthy individuals. They also identified specific bacterial patterns linked to MRI features associated with a less favorable MS prognosis. These features include a high lesion burden, the presence of spinal cord lesions, infratentorial lesions (affecting lower brain parts), and active inflammatory lesions. The study, published in eBioMedicine, analyzed stool samples from 53 adults with MS and 55 healthy controls, all newly diagnosed and not yet on disease-modifying therapies. The findings suggest that gut microbial profiling could serve as an early prognostic biomarker for MS, potentially aiding in identifying patients at higher risk of a negative disease course.

Mizzou Alum John Ruth Drives $10 Million State Investment for Rare Disease Research, Establishes Center for Translational Neurogenetics

Mizzou Alum John Ruth Drives $10 Million State Investment for Rare Disease Research, Establishes Center for Translational Neurogenetics

John Ruth, a University of Missouri (Mizzou) alumnus, has spearheaded a significant initiative resulting in a $10 million investment from the state of Missouri to fund research into rare genetic disorders. This funding has led to the establishment of the Center for Translational Neurogenetics (CTN) at Mizzou. Ruth's advocacy was motivated by his daughter, Kamdyn, who was diagnosed with Baker-Gordon Syndrome, an ultra-rare neurodevelopmental disorder caused by an SYT1 gene mutation. Through the Genetic Autism Alliance, an independent nonprofit he founded, Ruth championed the cause for increased research into such conditions, which often lack private industry investment due to their rarity. Mizzou researchers at the CTN have already developed a gene-editing technique called CRISPR-SWITCH, creating a preclinical model of Baker-Gordon Syndrome that more accurately reflects the human condition, offering new avenues for study and potential therapeutic development.

Dr. Jason W. Siefferman Launches 'Care Beyond the Pain' Podcast to Explore Chronic Pain Journeys

Dr. Jason W. Siefferman Launches 'Care Beyond the Pain' Podcast to Explore Chronic Pain Journeys

Dr. Jason W. Siefferman, Founder and Medical Director of Manhattan Pain Medicine, has launched a weekly podcast titled 'Care Beyond the Pain.' The podcast aims to provide a comprehensive understanding of chronic pain by featuring conversations with various individuals involved in the chronic pain journey, including patients, families, physicians, and specialists. Each episode delves into different aspects of chronic pain, offering context for patients and their families on how to navigate care, evaluate treatment options, manage setbacks, and understand the nature of progress. For clinicians and healthcare professionals, the podcast offers diverse perspectives across specialties, fostering a more complete understanding of complex pain conditions. The latest episode, S1E1, specifically addresses the challenge of 'When Pain Doesn’t Show Up on a Scan.' The podcast's goal is to bring together experiences, expertise, and questions to make the chronic pain journey more understandable, rather than providing indiv...

FDA Approves Moderna's mFLUSIVA, First mRNA Flu Vaccine for Adults 50 and Older

FDA Approves Moderna's mFLUSIVA, First mRNA Flu Vaccine for Adults 50 and Older

The U.S. Food and Drug Administration (FDA) has approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based influenza vaccine, for adults aged 50 years and older. This marks the first mRNA flu vaccine to receive FDA approval. The approval for adults aged 50 through 64 years is traditional, while for those 65 and older, it was granted through an accelerated pathway, requiring further confirmatory evidence of clinical benefit. The pivotal FLUENT phase 3 trial, which involved over 40,000 adults aged 50 and above, demonstrated that mFLUSIVA had a 26.6% greater relative efficacy against confirmed influenza-like illness compared to a licensed standard-dose influenza vaccine. The mRNA technology instructs cells to train the immune system, and its manufacturing process does not require the propagation of vaccine viruses in eggs, potentially allowing for faster production closer to the flu season. Side effects reported for mFLUSIVA are similar to other vaccines, including mild reactions such as fatigue, muscle and joint ac...

Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics Revolutionizes Cancer Treatment Decisions Through Genomic Analysis

Oncogenomics is a specialized field focused on the genomic analysis of tumors to guide cancer treatment decisions. This approach involves studying mutations in oncogenes and tumor suppressor genes, which are critical in the transformation of healthy cells into malignant ones. By understanding these genetic alterations, oncogenomics plays a pivotal role in personalized medicine, allowing for treatments to be tailored to an individual's unique genetic profile. This customization aims to reduce adverse reactions and improve overall healthcare outcomes. The open-access journal Oncotarget actively publishes research across all aspects of oncology, highlighting the ongoing advancements and importance of this field in medical research and practice. Personalized medicine, which includes oncogenomics, has been gaining momentum since the Human Genome Project's completion in 2003, enabling rapid advancements in genetic testing to identify disease-associated mutations.